Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network

Heinz Ludwig; Michel Delforge; Thierry Facon; Hermann Einsele; Francesca Gay; Philippe Moreau; Hervé Avet-Loiseau; Mario Boccadoro; Roman Hajek; Mohamad Mohty; Michele Cavo; Meletios A. Dimopoulos; Jesús F. San-Miguel; Evangelos Terpos; Sonja Zweegman; Laurent Garderet; Mariá-Victoria Mateos; Gordon Cook; Xavier Leleu; Hartmut Goldschmidt; Graham Jackson; Martin Kaiser; Katja Weisel; Niels W. C. J. van de Donk; Anders Waage; Meral Beksac; Ulf H. Mellqvist; Monika Engelhardt; Jo Caers; Christoph Driessen; Joan Bladé; Pieter Sonneveld

doi:https://doi.org/10.1038/s41375-018-0040-1

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network

Heinz Ludwig, Michel Delforge, Thierry Facon, Hermann Einsele, Francesca Gay, Philippe Moreau, Hervé Avet-Loiseau, Mario Boccadoro, Roman Hajek, Mohamad Mohty, Michele Cavo, Meletios A. Dimopoulos, Jesús F. San-Miguel, Evangelos Terpos, Sonja Zweegman, Laurent Garderet, Mariá-Victoria Mateos, Gordon Cook, Xavier Leleu, Hartmut GoldschmidtGraham Jackson, Martin Kaiser, Katja Weisel, Niels W. C. J. van de Donk, Anders Waage, Meral Beksac, Ulf H. Mellqvist, Monika Engelhardt, Jo Caers, Christoph Driessen, Joan Bladé, Pieter Sonneveld

Research output: Contribution to journal › Review article › Academic › peer-review

67 Citations (Scopus)

Abstract

During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.

Original language	English
Pages (from-to)	1542-1560
Journal	Leukemia
Volume	32
Issue number	7
Early online date	18 Dec 2017
DOIs	https://doi.org/10.1038/s41375-018-0040-1
Publication status	Published - 2018

Keywords

Journal Article
Review

Access to Document

https://doi.org/10.1038/s41375-018-0040-1

Cite this

Ludwig, H., Delforge, M., Facon, T., Einsele, H., Gay, F., Moreau, P., Avet-Loiseau, H., Boccadoro, M., Hajek, R., Mohty, M., Cavo, M., Dimopoulos, M. A., San-Miguel, J. F., Terpos, E., Zweegman, S., Garderet, L., Mateos, M.-V., Cook, G., Leleu, X., ... Sonneveld, P. (2018). Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. Leukemia, 32(7), 1542-1560. https://doi.org/10.1038/s41375-018-0040-1

@article{7ec5da7d9c0f40a9bee8616ebb5d49eb,

title = "Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network",

abstract = "During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.",

keywords = "Journal Article, Review",

author = "Heinz Ludwig and Michel Delforge and Thierry Facon and Hermann Einsele and Francesca Gay and Philippe Moreau and Herv{\'e} Avet-Loiseau and Mario Boccadoro and Roman Hajek and Mohamad Mohty and Michele Cavo and Dimopoulos, {Meletios A.} and San-Miguel, {Jes{\'u}s F.} and Evangelos Terpos and Sonja Zweegman and Laurent Garderet and Mari{\'a}-Victoria Mateos and Gordon Cook and Xavier Leleu and Hartmut Goldschmidt and Graham Jackson and Martin Kaiser and Katja Weisel and {van de Donk}, {Niels W. C. J.} and Anders Waage and Meral Beksac and Mellqvist, {Ulf H.} and Monika Engelhardt and Jo Caers and Christoph Driessen and Joan Blad{\'e} and Pieter Sonneveld",

year = "2018",

doi = "https://doi.org/10.1038/s41375-018-0040-1",

language = "English",

volume = "32",

pages = "1542--1560",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "7",

}

Ludwig, H, Delforge, M, Facon, T, Einsele, H, Gay, F, Moreau, P, Avet-Loiseau, H, Boccadoro, M, Hajek, R, Mohty, M, Cavo, M, Dimopoulos, MA, San-Miguel, JF, Terpos, E, Zweegman, S, Garderet, L, Mateos, M-V, Cook, G, Leleu, X, Goldschmidt, H, Jackson, G, Kaiser, M, Weisel, K, van de Donk, NWCJ, Waage, A, Beksac, M, Mellqvist, UH, Engelhardt, M, Caers, J, Driessen, C, Bladé, J & Sonneveld, P 2018, 'Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network', Leukemia, vol. 32, no. 7, pp. 1542-1560. https://doi.org/10.1038/s41375-018-0040-1

TY - JOUR

T1 - Prevention and management of adverse events of Novel agents in multiple myeloma

T2 - A consensus of the european myeloma network

AU - Ludwig, Heinz

AU - Delforge, Michel

AU - Facon, Thierry

AU - Einsele, Hermann

AU - Gay, Francesca

AU - Moreau, Philippe

AU - Avet-Loiseau, Hervé

AU - Boccadoro, Mario

AU - Hajek, Roman

AU - Mohty, Mohamad

AU - Cavo, Michele

AU - Dimopoulos, Meletios A.

AU - San-Miguel, Jesús F.

AU - Terpos, Evangelos

AU - Zweegman, Sonja

AU - Garderet, Laurent

AU - Mateos, Mariá-Victoria

AU - Cook, Gordon

AU - Leleu, Xavier

AU - Goldschmidt, Hartmut

AU - Jackson, Graham

AU - Kaiser, Martin

AU - Weisel, Katja

AU - van de Donk, Niels W. C. J.

AU - Waage, Anders

AU - Beksac, Meral

AU - Mellqvist, Ulf H.

AU - Engelhardt, Monika

AU - Caers, Jo

AU - Driessen, Christoph

AU - Bladé, Joan

AU - Sonneveld, Pieter

PY - 2018

Y1 - 2018

N2 - During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.

AB - During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.

KW - Journal Article

KW - Review

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85046372246&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/29720735

U2 - https://doi.org/10.1038/s41375-018-0040-1

DO - https://doi.org/10.1038/s41375-018-0040-1

M3 - Review article

C2 - 29720735

SN - 0887-6924

VL - 32

SP - 1542

EP - 1560

JO - Leukemia

JF - Leukemia

IS - 7

ER -

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network

Abstract

Keywords

Access to Document

Other files and links

Cite this